How Investors Are Reacting To Plexus (PLXS) Analyst Upgrades and Raised 2025 Earnings Estimates

• Earlier this month, Plexus Corp. saw its fiscal 2025 earnings estimates raised by two analysts, reflecting growing confidence in the company's performance across sectors such as Healthcare, Industrial, and Aerospace/Defense.
• This shift, together with Plexus's strong momentum scores and positive analyst outlook, underscores enhanced investor interest and an improved financial outlook for the company.
• We'll examine how these upward analyst revisions to Plexus's earnings estimates may influence its future earnings expectations and valuation narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Plexus Investment Narrative Recap

To believe in Plexus as a shareholder today, you need confidence in its ability to continuously secure new program wins in growth-focused sectors such as Healthcare and Aerospace/Defense, while managing cyclical revenue swings and customer concentration risk. The recent upward revisions in earnings estimates by two analysts reinforce momentum, but the most important near-term catalyst remains sustained contract wins in high-margin sectors; meanwhile, the biggest risk continues to be order volatility from large customers, a factor the latest analyst upgrades may not fully resolve. Of the recent announcements, the July 2025 Q3 earnings report stands out: Plexus posted higher sales and net income compared to the year prior, highlighting operational execution and profit improvement. While this supports higher analyst confidence, customer-related demand fluctuations continue to represent the key uncertainty hanging over the positive earnings trajectory. Yet it’s essential to recognize that when new contract momentum slows or single-customer ramp-ups falter, investors could face...

Read the full narrative on Plexus (it's free!)

Plexus' outlook anticipates $4.8 billion in revenue and $202.1 million in earnings by 2028. This scenario calls for a 6.1% annual revenue growth rate and a $39.4 million increase in earnings from the current $162.7 million.

Uncover how Plexus' forecasts yield a $154.60 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Only one estimate from the Simply Wall St Community values Plexus at US$114.18, reflecting extremely limited diversity in private investor outlooks. With recent earnings upgrades but persistent customer concentration risk, you may want to compare these perspectives for a broader view.

Explore another fair value estimate on Plexus - why the stock might be worth as much as $114.18!

Build Your Own Plexus Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Plexus research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Plexus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Plexus' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com